Esperion Therapeutics Acquired by Athyrium Capital Management | Healthcare M&A Deal

Athyrium Capital Management has completed the acquisition of Esperion Therapeutics, a pharmacy business in New York, for $50 million. Athyrium Capital Management acquisitions are structured as a Japan royalty financing tied to Esperion’s bempedoic acid royalty interest from Otsuka net sales, with tiered royalties of 12% to 33% plus regulatory and commercial milestone payments. Esperion Therapeutics acquisition supports the company’s healthcare M&A strategy to fund the acquisition of Corstasis Therapeutics, which developed and commercializes Enbumyst, an FDA-approved intranasal loop diuretic for edema tied to cardiovascular and hepatic and renal disease. The private equity acquisition is categorized as other acquisition and is expected to close under the announced $50 million royalty financing agreement, with rights reverting to Esperion after Athyrium receives aggregate payments equal to 2.0x its investment.